Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Co‐treatment of non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization

Clinical & Experimental Allergy(2023)10.1111/cea.14348Source: DataRank Database

Co‐treatment of non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization is a research paper published in Clinical & Experimental Allergy (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.72)OA: bronzeTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Jonathan Hacker,Rie Maurer ORCID,Alanna McGill,Tessa Ryan ORCID,Jillian C. Bensko ORCID

Live enrichment

PubMed:37246613 PMC:PMC10524624 OpenAlex:https://openalex.org/W4378640259

National Institutes of Health

Grant: R01HL128241

NIAID NIH HHS

Grant: U19 AI095219

NIAID NIH HHS

Grant: T32 AI007306

NIAID NIH HHS

Grant: K23 AI139352

Regeneron Pharmaceuticals

FWCI

0.72

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

bronze

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cea.14348

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cea.14348

journalhttps://doi.org/10.1111/cea.14348

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37246613

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10524624

Fields of Study

Asthma and respiratory diseasesDrug-Induced Adverse ReactionsInflammatory mediators and NSAID effects

MeSH Terms

Anti-Inflammatory Agents, Non-SteroidalAspirinChronic DiseaseDesensitization, ImmunologicHumansNasal PolypsRespiratory Tract DiseasesRhinitisAsthma, Aspirin-InducedAntibodies, Monoclonal, Humanized

Keywords

Desensitization (medicine)DupilumabMedicineAspirinDrugDiseaseRespiratory systemRescue therapyPharmacotherapyRespiratory diseaseImmunologyPharmacologyIntensive care medicineInternal medicineAsthmaLungReceptorNasal polypsAspirin DesensitizationChronic RhinosinusitisAspirin-exacerbated Respiratory DiseaseNsaid-exacerbated Respiratory DiseaseAspirin Therapy After Desensitization

Sustainable Development Goals

SDG 0: Good health and well-being